3,271
Views
23
CrossRef citations to date
0
Altmetric
Commentary

Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines

ORCID Icon, & ORCID Icon
Pages 2965-2968 | Received 11 Feb 2021, Accepted 15 Apr 2021, Published online: 05 May 2021

Figures & data

Figure 1. Immune response after immunization with rRBD from Sars-Cov-2 with aluminum hydroxide plus OMV from Neisseria meningitidis strains B:8:P1.6 (prep1) or C:2a.P1.5 (prep2). The IgG production in sera collected 15 and 45 days after the first immunization dose was measured by ELISA and can be observed in (a). The IgA production was accessed 15, 30, 37 and 45 days after the first immunization dose (b). Additionally, 45 days after the first immunization dose, the animals were euthanized and the splenocytes were cultured under rRBD stimuli. The IgG production in culture supernatant was evaluated by ELISA (c) and the number of cells/106 splenocytes producing IFN-γ (d) or IL-17 (e) was evaluated through ELISpot

Figure 1. Immune response after immunization with rRBD from Sars-Cov-2 with aluminum hydroxide plus OMV from Neisseria meningitidis strains B:8:P1.6 (prep1) or C:2a.P1.5 (prep2). The IgG production in sera collected 15 and 45 days after the first immunization dose was measured by ELISA and can be observed in (a). The IgA production was accessed 15, 30, 37 and 45 days after the first immunization dose (b). Additionally, 45 days after the first immunization dose, the animals were euthanized and the splenocytes were cultured under rRBD stimuli. The IgG production in culture supernatant was evaluated by ELISA (c) and the number of cells/106 splenocytes producing IFN-γ (d) or IL-17 (e) was evaluated through ELISpot

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.